News about "exclusive licensing agreement"

Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK

Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK

Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.

Exclusive Licensing Agreement | 25/02/2026 | By News Bureau 147

Formosa Pharmaceuticals Partners with Arrotex Pharmaceuticals to Commercialise APP13007 in Australia and New Zealand

Formosa Pharmaceuticals Partners with Arrotex Pharmaceuticals to Commercialise APP13007 in Australia and New Zealand

Exclusive licensing deal grants Arrotex rights to market clobetasol propionate ophthalmic suspension for post-surgical ocular inflammation and pain, expanding Formosa’s footprint in Oceania.

Exclusive Licensing Agreement | 23/02/2026 | By News Bureau

Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist

Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist

Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.

Exclusive Licensing Agreement | 30/12/2025 | By News Bureau 135

Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US

Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US

Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.

Exclusive Licensing Agreement | 05/12/2025 | By Dineshwori 114

Glenmark Secures China's Approval For RYALTRIS

Glenmark Secures China's Approval For RYALTRIS

Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.

Exclusive Licensing Agreement | 11/11/2025 | By Dineshwori 359


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members